Skip to main content
Sameer Parikh, MD, Oncology, Rochester, MN, Mayo Clinic Hospital - Rochester

SameerAshokParikhMD

Oncology Rochester, MN

Hematologic Oncology

Associate Professor, Internal Medicine, Mayo Medical School

Dr. Parikh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Parikh's full profile

Already have an account?

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2011 - 2014
  • Ascension Illinois/Saint Francis
    Ascension Illinois/Saint FrancisResidency, Internal Medicine, 2002 - 2005
  • Seth G.S. Medical College
    Seth G.S. Medical CollegeClass of 2001

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2010 - 2024
  • TX State Medical License
    TX State Medical License 2005 - 2011
  • IL State Medical License
    IL State Medical License 2002 - 2005

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre  
    Sameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology

Abstracts/Posters

  • Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
    Sameer A. Parikh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition is Mechanistically Supported By a Novel Direct Interaction of G...
    Sameer A. Parikh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (C...
    Sameer A. Parikh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Case 1: Newly Diagnosed CLL, IGHV-Unmutated
    Case 1: Newly Diagnosed CLL, IGHV-UnmutatedJanuary 28th, 2020

Professional Memberships

Hospital Affiliations